Ipamorelin
NNC 26-0161, Ipamorelin acetate, "Ipa" (community shorthand); CAS 170851-70-4
The Ground Truth Score
four plain questions, never one numberReal human trials exist, and they failed
Bottom line
Unusually for a gray-market peptide it reached Phase 2 human RCTs, but those trials were for gut motility (not the muscle/recovery/anti-aging uses it is sold for), failed their primary endpoint, and the program was discontinued, so the popular use case rests almost entirely on mechanism plus anecdote.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (not prescribed) community/clinic use is typically 200–300 mcg subcutaneously per injection, 1–3x/day, with the pre-bed dose treated as most important to align with the natural nocturnal GH pulse.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Human pharmacokinetic/pharmacodynamic dosing was characterized around the late 1990s–2000s by Novo Nordisk, and the first published randomized controlled human trial was Helsinn Therapeutics' Phase 2 postoperative-ileus study (NCT00672074, results published Beck et al., Int J Colorectal Dis, December 2014). Critically, NO controlled human trial has ever tested ipamorelin for the body-composition, recovery, sleep or anti-aging outcomes for which it is actually marketed.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- A selective ghrelin/GHS-receptor agonist that triggers a short, pulsatile release of the body's own growth hormone.
- Marketed as 'cleaner' than older GHRPs (GHRP-2/GHRP-6) because in trials it raised GH without meaningfully raising cortisol, prolactin or ACTH.
- Commonly stacked with CJC-1295 (a GHRH analog) on the theory that the two act on complementary pathways for a larger GH pulse.
- Reached Phase 2 human trials (for a different indication) and was generally well tolerated, which is more clinical exposure than most gray-market peptides have.
- Reportedly used at low microgram doses for recovery, sleep quality and gradual fat-loss/lean-mass support.
The data behind each bullet
What actually backs it
Ipamorelin is a selective growth-hormone secretagogue that raises GH without significantly raising ACTH, cortisol, or prolactin, the core mechanistic claim.
Demonstrated in the foundational animal/in-vitro work (Raun et al., 1998, rat pituitary cells, rats, swine) and consistent with its receptor selectivity; GH-raising effect also observed in human PK/PD work. Selectivity is well-supported mechanistically but the cleanest data are preclinical.
Raun 1998, first selective GH secretagogue (PubMed) ↗Ipamorelin improves a clinically meaningful human outcome.
The strongest human test (Phase 2 RCT for postoperative ileus, ~117 patients) was NEGATIVE: authors reported it 'did not shorten the time to first meal intake' and showed 'no significant difference in measurable colonic functions' vs placebo. A second, larger Phase 2 (n=320) was also run; the program was discontinued for lack of efficacy. This is a rare case where human RCT data exists and argues against efficacy for the tested endpoint.
Beck 2014 proof-of-concept RCT, postoperative ileus (PubMed search) ↗Ipamorelin builds muscle, reduces fat, or slows aging in humans.
No controlled human trial has tested these outcomes. Body-weight/lean-mass effects are documented only in animals. The popular use case is an extrapolation from short-term GH pulses, not a measured human result.
Ipamorelin clinical trials registry (ClinicalTrials.gov) ↗It is FDA-approved or an established prescription therapy.
Ipamorelin is not FDA-approved for any indication. It is sold as a 'research peptide' and was a focus of FDA compounding restrictions (Category 2, immunogenicity concerns). Any therapeutic use is off-label/gray-market.
FDA compounding / peptide category materials (FDA.gov) ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed mechanism (not an approved drug): ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a), a G-protein-coupled receptor on the anterior pituitary. This triggers a short, pulsatile release of the body's own growth hormone, which in turn raises IGF-1. Its selling point is selectivity, in trials it did this without meaningfully raising cortisol, prolactin, or ACTH. The downstream body-composition and recovery benefits people seek are inferred from GH/IGF-1 biology, not directly demonstrated.
Dosing & handling
What users and clinicians report
Reported (not prescribed) community/clinic use is typically 200–300 mcg subcutaneously per injection, 1–3x/day, with the pre-bed dose treated as most important to align with the natural nocturnal GH pulse. Often run in cycles (e.g., several weeks on) and frequently paired with CJC-1295. Clinical trials used a different route and scale entirely (IV, ~0.03 mg/kg).
These numbers are forum/clinic conventions, not validated protocols, and the human trials that exist used IV hospital dosing for a different purpose. Doses are mcg (micrograms), easy to mis-measure with insulin syringes after reconstitution. Gray-market vials may not contain the labeled amount, so 'dose' is only as real as the source.
Timing & food
Most commonly reported timing is at bedtime on an empty stomach (and/or fasted in the morning). The fasted rule exists because food, especially carbohydrate/insulin, blunts GH secretion; users typically leave a gap of roughly 1–2 hours after eating before dosing and ~20–30 minutes before eating after. The pre-bed dose is prioritized to stack on the body's largest natural GH pulse during early deep sleep.
Half-life
Terminal elimination half-life is approximately 2 hours in humans, with rapid clearance, hence the rationale for multiple daily doses and the emphasis on a pre-bed dose to overlap the natural nighttime GH surge.
Reconstitution sensitivity
Supplied as a lyophilized powder; reconstituted with bacteriostatic water. Sensitive to handling: add diluent slowly down the vial wall, swirl gently, do not shake or vortex (agitation degrades peptide). Lyophilized vials are stable long-term frozen/cold; once reconstituted, refrigerate at 2–8 C and use within roughly 3–4 weeks. Avoid heat excursions and avoid re-freezing the reconstituted solution. Keep on an interior fridge shelf, not the door.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
High volume of discussion, ipamorelin (usually as 'CJC-1295/Ipamorelin') is one of the most widely used and talked-about GH peptides across bodybuilding, biohacking, TRT, and anti-aging-clinic communities, with extensive forum threads and clinic marketing.
Consistency
Moderately consistent on the subjective side: users commonly report better sleep and recovery, mild fat loss, and gradual lean-mass/skin improvements over weeks-to-months. But reports of dramatic effects are inconsistent, a meaningful minority report 'felt nothing,' and almost all positive reports come from people also running CJC-1295 and/or other compounds, so the consistency is in the narrative, not in clean attribution.
Source credibility
Mixed-to-low source credibility. A large share of favorable content is from peptide vendors, compounding pharmacies, and wellness clinics with a financial interest (discounted here). Independent, non-commercial user reports exist and skew 'mild, gradual, subtle' rather than transformative, and notably the one rigorous human readout (the postoperative-ileus RCT) was negative, which should anchor expectations more than forum sentiment.
- Anecdote, not proof: the most common report is improved sleep quality and quicker workout recovery within the first few weeks, often described as subtle rather than dramatic.
- Many users report gradual changes in body composition (slightly leaner, better skin, modest lean-mass gains) over 2–3+ months, almost always while also running CJC-1295 and usually alongside training/diet changes.
- A recurring minority report little or no perceptible effect, and some note tolerance/diminishing returns over a cycle, prompting on/off cycling.
- Mild, transient complaints show up regularly: head-rush or lightheadedness right after injection, occasional water retention or tingling in the hands, and head/face flushing; most call it well tolerated at low doses.
Placebo risk, Moderate
The headline benefits people chase, better sleep, faster recovery, 'feeling younger,' subtle body recomposition, are largely subjective, slow, and easily confounded by diet, training, the bedtime ritual, and co-administered compounds, which is fertile ground for placebo and expectancy effects. It is not rated High because the underlying biology is real and partially objective: ipamorelin does measurably raise GH/IGF-1, and GH/IGF-1 can be blood-tested. Users who actually verify with labs (rather than relying on feel) move themselves toward the lower-placebo end.
Risk panel
What could go wrong
Adverse events
In trials and clinic reports, adverse effects are usually mild: injection-site irritation, headache, transient dizziness/lightheadedness (possible brief blood-pressure dip), fatigue, nausea, and mild fluid retention (tingling/puffy hands or ankles) at higher GH exposure. It was described as well tolerated across hundreds of Phase 2 patients on IV dosing.
Theoretical concerns
Anything that repeatedly stimulates the GH/IGF-1 axis carries theoretical concerns: insulin resistance / impaired glucose tolerance, fluid retention, joint aches, and, over the long term and unstudied at these doses, the general worry that chronically elevated IGF-1 could promote growth of existing tumors. As a ghrelin-receptor agonist it can also influence appetite. None of this is established as harmful at reported microgram doses, but none of it is reassured by long-term human data either.
Contraindications
Reasonably avoided by anyone with active or prior malignancy, during pregnancy/breastfeeding, in children/adolescents (open growth plates), and used cautiously with diabetes/insulin resistance. The FDA flagged immunogenicity (immune reaction to the peptide) as a concern for this class. The single largest practical risk is product quality: unregulated 'research-only' vials with uncertain purity, dose, sterility, or contaminants.
Honest unknowns
No long-term human safety data at the doses people actually use; no human data at all for the body-composition/anti-aging use case; unknown effects of years of intermittent GH pulsing; and unknown real-world content of gray-market product. The honest unknown is large.
Confound watch
Ipamorelin is very rarely taken alone, it is almost always combined with CJC-1295 (and frequently alongside TRT/testosterone, tesamorelin, BPC-157, GLP-1 agonists, or an aggressive diet-and-training block). Bedtime dosing also coincides with sleep, so 'better sleep/recovery' is hard to separate from simply having a nighttime routine. Attribution to ipamorelin specifically is therefore weak.
History
Discovery → first use → status
- 1998Raun et al. (Novo Nordisk) publish ipamorelin as 'the first selective growth hormone secretagogue' (NNC 26-0161) in animal/in-vitro models. European Journal of Endocrinology.
- Late 1990s–2000sHuman PK/PD dosing characterized; terminal half-life ~2 hours. Novo Nordisk does not advance it as an approved GH product.
- 2008–2014Helsinn Therapeutics runs Phase 2 trials for postoperative ileus: NCT00672074 (~117 patients) and the larger NCT01280344 (~320 patients), IV dosing.
- December 2014Beck et al. publish the proof-of-concept RCT: ipamorelin did NOT significantly improve bowel-function recovery vs placebo (Int J Colorectal Dis).
- ~2015 onwardClinical program discontinued for lack of efficacy; ipamorelin migrates into the gray-market 'research peptide' / wellness-clinic space, usually stacked with CJC-1295.
- 2023–2026Caught up in FDA peptide-compounding restrictions; in 2026 reporting suggests several of those peptides may move back toward compounding eligibility, but ipamorelin remains non-FDA-approved.
Verification
The COA standard, applied
Cross-checked the foundational pharmacology (Raun 1998, PubMed 9849822), two Helsinn Phase 2 trials (NCT00672074 n=117; NCT01280344 n=320) on ClinicalTrials.gov, the negative proof-of-concept publication (Beck et al. 2014, Int J Colorectal Dis), and regulatory status (non-FDA-approved, compounding-restricted). Community/clinic dosing and side-effect reports were read against, and discounted relative to, the peer-reviewed and registry sources; vendor pages were treated as non-evidence.
The full verification standard →Sources
Where this comes from
- Raun et al. 1998, 'Ipamorelin, the first selective growth hormone secretagogue' (PubMed 9849822) ↗· Foundational pharmacology; animal/in-vitro; establishes GH selectivity vs ACTH/cortisol/prolactin.
- Ipamorelin postoperative-ileus RCT literature. Beck et al. 2014 (PubMed search) ↗· Proof-of-concept Phase 2 RCT in bowel-resection patients; NEGATIVE on primary endpoint.
- Ipamorelin Phase 2 trial NCT00672074 (ClinicalTrials.gov) ↗· Helsinn, ~117 patients, IV, postoperative ileus; completed, no results posted; program later discontinued.
- Ipamorelin Phase 2 trial NCT01280344 (ClinicalTrials.gov) ↗· Helsinn, ~320 patients, multiple IV dose arms, GI dysmotility; completed 2014, no results posted.
- All ipamorelin trials (ClinicalTrials.gov search) ↗· Confirms human trials are limited to GI-motility indications; none for body composition/anti-aging.
- Ipamorelin GH-secretagogue evidence (PubMed search) ↗· Broader literature base for mechanism, selectivity, and half-life (~2 h).
- FDA, bulk drug substances for 503B compounding (regulatory status) ↗· Context for non-FDA-approved status and compounding/immunogenicity concerns.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.